Previous 10 | Next 10 |
2023-11-13 07:56:03 ET More on Aclaris Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer Aclaris Therapeutics rises 13% on insider buy Seeking Alpha’s Quant Rating on Aclaris Therapeutics Historical earnings data for Aclaris Ther...
— Study Did Not Meet Primary or Secondary Efficacy Endpoints in Rheumatoid Arthritis — — Efficacy Results Do Not Support Further Development of Zunsemetinib — — Company to Host Conference Call and Webcast Today at 8:00 AM ET ...
Aclaris Therapeutics Inc. (ACRS) is expected to report $-0.48 for Q3 2023
2023-11-06 07:20:03 ET More on Aclaris Therapeutics Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer Aclaris Therapeutics rises 13% on insider buy Seeking Alpha’s Quant Rating on Aclaris Therapeutics Historical earnings data for...
2023-10-04 17:50:03 ET Gainers: Prime Medicine ( NASDAQ: PRME ) +5% . uniQure ( QURE ) +5% . Aclaris Therapeutics ( ACRS ) +4% . ALX Oncology Holdings ( ALXO ) +3% . Aurora Innovation ( AUR ) +3% . Losers: MaxCy...
- Top-line Data Anticipated Around Year End WAYNE, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the completion of...
2023-09-28 17:12:16 ET Gainers: Editas Medicine ( NASDAQ: EDIT ) +8% . Marqeta ( MQ ) +3% . Cipher Mining ( CIFR ) +3% . Aclaris Therapeutics ( ACRS ) +2% . Biora Therapeutics ( BIOR ) +2% . Losers: Jaguar Global Grow...
2023-09-28 07:18:10 ET Summary Aclaris Therapeutics is a developer of kinome-based medicines for immune-inflammatory and oncology indications. The company's platform, KINect, helps advance small molecules targeting kinases to replicate or improve the effects of expensive biologics...
WAYNE, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fire...
– Preliminary Data Support Progression to Phase 2a Proof of Concept Trials in T cell-mediated Autoimmune Diseases – WAYNE, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on dev...
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company ...
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will part...
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...